Patent · US Active

Modified relaxin B chain peptides and their therapeutic use

US10988524B2 · kind B2 · utility

1Cited by

1References

20Claims

0Family size

Assignee

Sanofi · FR

Inventors

Stéphane Illiano · Paris, FR
Sergio Mallart · Paris, FR
Claire Minoletti-Hochepied · Paris, FR
Frank Marguet · Verrières-le-Buisson, FR
Olivier Duclos · Paris, FR
Elisabetta Bianchi · Pomezia, IT
Raffaele Ingenito · Pomezia, IT
Paola Magotti · Frederiksværk, DK
Alessia Santoprete · Pomezia, IT

Key dates

Filing date	Jan 31, 2019
Grant date	Apr 27, 2021
Priority date	—
Expiry date	Jan 31, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided is a biologically active single chain Relaxin peptide having the following formula (I): Nter-X-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(X34)d-NH2-Cter. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, or a pharmaceutically acceptable salt or a solvate thereof. Further provided is the peptide, a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition for use as a medicament.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.